Professor Naveed Sattar wins EASD’s Camillo Golgi Prize

By Editor
24th April 2020
Good practice, Type 2 diabetes Type 2 prevention

A Metabolic Medicine professor based in Scotland has been awarded the prestigious Camillo Golgi Prize by the European Association for the Study of Diabetes (EASD).

Professor Naveed Sattar, from the University of Glasgow and Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary University, was contacted by Chairman of the Camillo Golgi award Committee, to be told he had scooped the prize.

It’s fair to say that few diabetes researchers have done as much as Naveed Sattar across most of the above CVD-related domains, leading to a reputation of excellence in understanding and explaining CVD risk in diabetes Professor Martin Rutter

The award is presented to someone who has provided outstanding contributions in the field of histopathology, pathogenesis, prevention and treatment of the complications of diabetes which have been carried out in Europe by a member of EASD.

Professor Sattar said: “It’s a huge honour to have been chosen as the recipient of this award and to have my work recognised on a European scale is hugely rewarding. I am very appreciative to my excellent colleague and friend, Professor Martin Rutter who took the time to submit my nomination, but also to the incredible and dedicated people I have worked with throughout my career, who without them, I simply would not have been able to have done a lot of the research I’ve carried out.”

In his 25-year career Professor Sattar has contributed to nearly 1,000 research papers and nearly a third relate in some way to diabetes and cardiovascular disease. His papers have helped improve the understanding of pathogenesis of cardiovascular disease (CVD) in diabetes and have aided CVD preventative efforts.

Some of the key papers he has worked on have featured heavily in relevant national and international guidelines. In addition, Professor Sattar has been invited to sit on several steering committees of ongoing outcome trials in diabetes, which include relevant trials in CVD prevention.

He has specifically worked on some of the major epidemiology findings of CVD risk in diabetes in relation to age of onset, sex and ethnicity, as well working in type 2 diabetes prevention, having been a part of the DiRECT trial.

In his nomination letter to EASD, Professor Rutter said: “It’s perhaps true to reflect that the biggest change in the risk and management of diabetes complications in the last one to two decades has come in cardiovascular disease (CVD), once diabetes’ biggest killer. The field has witnessed major changes in disease prevalence, CVD death rates, leading to CHD outcomes being less common and others (e.g. heart failure) more so.

“It’s fair to say that few diabetes researchers have done as much as Naveed Sattar across most of the above CVD-related domains, leading to a reputation of excellence in understanding and explaining CVD risk in diabetes.

“Naveed has often proposed different ways to look at the evidence, challenging conventional wisdom in a balanced and robust manner.”

The prestigious award is named after Camillo Golgi who was awarded the Noble Prize in 1906 for his studies on the nervous system and kidney physiology.

Comments (0)

Register an account or login to comment